|
1
|
Wen PY and Reardon DA: Neuro-oncology in
2015: rogress in glioma diagnosis, classification and treatment.
Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noushmehr H, Weisenberger DJ, Diefes K,
Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP,
Bhat KP, et al: Identification of a CpG island methylator phenotype
that defines a distinct subgroup of glioma. Cancer Cell.
17:510–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bigner DD, Bigner SH, Pontén J, Westermark
B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF and Wikstrand CJ:
Heterogeneity of genotypic and phenotypic characteristics of
fifteen permanent cell lines derived from human gliomas. J
Neuropathol Exp Neurol. 40:201–229. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diserens AC, de Tribolet N, Martin-Achard
A, Gaide AC, Schnegg JF and Carrel S: Characterization of an
established human malignant glioma cell line: LN-18. Acta
Neuropathol. 53:21–28. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Meir E, Sawamura Y, Diserens AC, Hamou
MF and de Tribolet N: Human glioblastoma cells release interleukin
6 in vivo and in vitro. Cancer Res. 50:6683–6688. 1990.PubMed/NCBI
|
|
7
|
Ishii N, Maier D, Merlo A, Tada M,
Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of
TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Meir EG, Kikuchi T, Tada M, Li H,
Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N and
Cavenee WK: Analysis of the p53 gene and its expression in human
glioblastoma cells. Cancer Res. 54:649–652. 1994.PubMed/NCBI
|
|
9
|
Bocchini V, Casalone R, Collini P, Rebel G
and Lo Curto F: Changes in glial fibrillary acidic protein and
karyotype during culturing of two cell lines established from human
glioblastoma multiforme. Cell Tissue Res. 265:73–81. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bian X, Yang Z, Feng H, Sun H and Liu Y: A
combination of species identification and STR profiling identifies
cross-contaminated cells from 482 human tumor cell lines. Sci Rep.
7:97742017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-Year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herrlinger U, Tzaridis T, Mack F,
Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D,
Grauer O, et al: Lomustine-temozolomide combination therapy versus
standard temozolomide therapy in patients with newly diagnosed
glioblas-0toma with methylated MGMT promoter (CeTeG/NOA-09): A
randomised, open-label, phase 3 trial. Lancet. 393:678–688. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Killock D: Lomustine-temozolomide
combination efficacious in newly diagnosed glioblastoma. Nat Rev
Clin Oncol. 16:2732019.
|
|
15
|
Wick W, Gorlia T, Bendszus M, Taphoorn M,
Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al:
Lomustine and bevacizumab in progressive glioblastoma. New Engl J
Med. 377:1954–1963. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jeremic B, Grujicic D, Jevremovic S,
Stanisavljevic B, Milojevic L, Djuric L and Mijatovic L:
Carboplatin and etoposide chemotherapy regimen for recurrent
malignant glioma: A phase II study. J Clin Oncol. 10:1074–1077.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buckner JC, Ballman KV, Michalak JC,
Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW,
Sandler HM, Marks RS, et al: Phase III trial of carmustine and
cisplatin compared with carmustine alone and standard radiation
therapy or accelerated radiation therapy in patients with
glioblastoma multiforme: North central cancer treatment group
93-72-52 and southwest oncology group 9503 trials. J Clin Oncol.
24:3871–3879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Snuderl M, Fazlollahi L, Le LP, Nitta M,
Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD,
Betensky RA, et al: Mosaic amplification of multiple receptor
tyrosine kinase genes in glioblastoma. Cancer Cell. 20:810–817.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yi GZ, Huang G, Guo M, Zhang X, Wang H,
Deng S, Li Y, Xiang W, Chen Z, Pan J, et al: Acquired temozolomide
resistance in MGMT-deficient glioblastoma cells is associated with
regulation of DNA repair by DHC2. Brain. 142:2352–2366. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McLendon R, Friedman A, Bigner D, Van Meir
EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N,
Aldape K, et al: Comprehensive genomic characterization defines
human glioblastoma genes and core pathways. Nature. 455:1061–1068.
2008. View Article : Google Scholar
|
|
22
|
Yao PS, Kang DZ, Wang XF, Lin RY and Ye
ZC: Cell-density-dependent manifestation of partial characteristics
for neuronal precursors in a newly established human gliosarcoma
cell line. In Vitro Cell Dev Biol Anim. 51:345–352. 2015.
View Article : Google Scholar
|
|
23
|
Notarangelo A, Trombetta D, D'Angelo V,
Parrella P, Palumbo O, Storlazzi CT, Impera L, Muscarella LA, La
Torre A, Affuso A, et al: Establishment and genetic
characterization of ANGM-CSS, a novel, immortal cell line derived
from a human glioblastoma multiforme. Int J Oncol. 44:717–724.
2014. View Article : Google Scholar
|
|
24
|
Li Y, Sun T, Chen Z, Shao Y, Huang Y and
Zhou Y: Characterization of a new human astrocytoma cell line
SHG140: Cell proliferation, cell phenotype, karyotype, STR markers
and tumorigenicity analysis. J Cancer. 12:371–378. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Wang H, Sun T, Chen J, Guo L, Shen
H, Du Z and Zhou Y: Biological characteristics of a new human
glioma cell line transformed into A2B5(+) stem cells. Mol Cancer.
14:752015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Man J, Yu X, Huang H, Zhou W, Xiang C,
Huang H, Miele L, Liu Z, Bebek G, Bao S and Yu JS: Hypoxic
induction of vasorin regulates notch1 turnover to maintain glioma
stem-like cells. Cell Stem Cell. 22:104–118.e6. 2018. View Article : Google Scholar :
|
|
27
|
Aubrey BJ, Strasser A and Kelly GL:
Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb
Perspect Med. 6:a0260622016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M,
Byrnes G, Zavadil J and Olivier M: TP53 variations in human
cancers: New lessons from the IARC TP53 database and genomics data.
Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cesare AJ and Reddel RR: Alternative
lengthening of telomeres: Models, mechanisms and implications. Nat
Rev Genet. 11:319–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Labussière M, Di Stefano AL, Gleize V,
Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y,
Rahimian A, et al: TERT promoter mutations in gliomas, genetic
associations and clinico-pathological correlations. Br J Cancer.
111:2024–2032. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dewhurst SM, McGranahan N, Burrell RA,
Rowan AJ, Grönroos E, Endesfelder D, Joshi T, Mouradov D, Gibbs P,
Ward RL, et al: Tolerance of whole-genome doubling propagates
chromosomal instability and accelerates cancer genome evolution.
Cancer Discov. 4:175–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim H, Nguyen NP, Turner K, Wu S, Gujar
AD, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, et al:
Extrachromosomal DNA is associated with oncogene amplification and
poor outcome across multiple cancers. Nat Genet. 52:891–897. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koche RP, Rodriguez-Fos E, Helmsauer K,
Burkert M, MacArthur IC, Maag J, Chamorro R, Munoz-Perez N,
Puiggròs M, Dorado Garcia H, et al: Extrachromosomal circular DNA
drives oncogenic genome remodeling in neuroblastoma. Nat Genet.
52:29–34. 2020. View Article : Google Scholar :
|
|
34
|
Nathanson DA, Gini B, Mottahedeh J,
Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et
al: Targeted therapy resistance mediated by dynamic regulation of
extrachromosomal mutant EGFR DNA. Science. 343:72–76. 2014.
View Article : Google Scholar :
|
|
35
|
Turner KM, Deshpande V, Beyter D, Koga T,
Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, et al:
Extrachromosomal oncogene amplification drives tumour evolution and
genetic heterogeneity. Nature. 543:122–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Percie du Sert N, Ahluwalia A, Alam S,
Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U,
Emerson M, et al: Reporting animal research: Explanation and
elaboration for the ARRIVE guidelines 2.0. PLoS Biol.
18:e30004112020. View Article : Google Scholar : PubMed/NCBI
|
